MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ensci.2022.100425

Медицинская библиотека · eNeurologicalSci · 2022

Acute subdural hematoma due to acute myeloid leukemia and B-cell lymphoma.

Babici D, Sharma P, DeGregorio J, Snelling B, Hanafy K

Перевод в очереди

Аннотация

Chloroma, is an rare malignant tumor characterized by the extramedullary blast proliferation of myeloid lineages that subsequently change the normal architecture of surrounding tissues. Because this is very rare disease, primary central nervous system myeloid sarcoma has not been widely reported. Myeloid sarcoma, as a group of heterogenetic diseases, presents with differential clinical and histological pictures depending upon the primary affected site. We are presenting a 77-year-old gentleman, with past medical history of chronic lymphoblastic leukemia that was not on any treatment and who presented with complaints of lethargy, disorientation, and weakness. CT scan of the head showed left-sided subdural hematoma with significant mass effect with left-to-right shift. Craniotomy and hematoma evacuation was performed and hematoma and subdural lesion was sent for pathological evaluation. Histologic examination of the hematoma revealed solid sheets of small-medium sized atypical hematopoietic cells that was imbedded in an acute and chronic hematoma. To confirm the final diagnosis, flow cytometry was performed and showed two neoplastic clones, consistent with acute myeloid leukemia with monocytic differentiation and a separate mature B-cell lymphoma. To our knowledge we are presenting the first case in the literature of the Intracranial acute myeloid leukemia/myeloid sarcoma and B-cell lymphoma that was found in the same brain lesion.

Для цитирования: Babici D, Sharma P, DeGregorio J, Snelling B, Hanafy K. Acute subdural hematoma due to acute myeloid leukemia and B-cell lymphoma.. eNeurologicalSci. 2022. DOI: 10.1016/j.ensci.2022.100425.

Перевод полного текста: Перевод в очереди

Полный текст источника

https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Chronic lymphocytic leukemia (CLL) is a myeloproliferative disease characterized by the presence of the Philadelphia chromosome, which results from the chromosomal translocation t(9;22)(q34;q11) [ 1 ]. The incidence of CLL is different worldwide, highest being in North America (7.99/100,000) [ 2 ]. CLL follows a long unexciting protracted course with low proliferative activity wherein the patient remains asymptomatic for years, not requiring any treatment or intervention but on the other hand, the disease may be characterized by lymphadenopathy, splenomegaly, anemia, and thrombocytopenia with rapid progression in the clinical and hematological course of the disease [ 2 ]. Over time CLL can be transformed into diffuse large B-cell lymphoma, Hogdkin's lymphoma, or B-cell prolymphocytic leukemia (PLL). Multiple myeloma and a hairy cell leukemia may also be developed in patients with CLL. However, transformation into acute lymphoblastic leukemia has rarely been reported. In the literature, only a few cases of acute leukemic transformation have been reported [ [3] , [4] , [5] , [6] , [7] , [8] , [9] , [10] ]. Primary CNS lymphoma (PCNSL) is a rare tumor representing <2% of intracranial neoplasms [ 11 , 12 ]. It is defined as a lymphoma outside of lymph nodes in the absence of systemic disease. Primary dural lymphomas (PDL) are very rare and are low-grade B-cell lymphomas [ 13 ]. PDL has a better prognosis than other PCNSLs. The incidence of PCNSL is higher in immunocompromised patients, whereas PDL is seen in immune competent patients. PDL is rare and very few cases are reported in the literature [ 14 , 15 ]. A differential diagnosis of other dura-based lesions includes, but is not limited to, meningioma, including atypical and anaplastic types, solitary fibrous tumor/hemangiopericytoma, and metastatic carcinoma.

Case presentation

A 77-year-old gentleman, with past medical history of Chronic Lymphoblastic Leukemia not on any treatment, hypertension, deep venous thrombosis on Rivaroxaban, was transferred from another hospital after presenting with complaints of lethargy, disorientation, and weakness. On the admission to the hospital patient was hemodynamically stable, but physical exam was significant for hemiparesis on the right side of the body and hemineglect on the left side and patient did not followed commands. Laboratory analysis was significant for white blood cell count of 70, hemoglobin of 6.7 and platelet count of 46. Due to elevated white blood cell count, broad spectrum antibiotics were started. CT scan of the head showed left-sided subdural hematoma with extension along the tentorium and interhemispheric fissure with significant mass effect with left-to-right shift ( Fig. 1 ). Fig. 1 CT scan of the brain. Left-sided subdural hematoma with extension along the tentorium and interhemispheric fissure with significant mass effect with left-to-right shift (Red Arrow). Fig. 1

Fig. 1 CT scan of the brain. Left-sided subdural hematoma with extension along the tentorium and interhemispheric fissure with significant mass effect with left-to-right shift (Re…
Fig. 1 CT scan of the brain. Left-sided subdural hematoma with extension along the tentorium and interhemispheric fissure with significant mass effect with left-to-right shift (Red Arrow). Fig. 1

Neurosurgery was consulted and decision was made to perfrom emergent craniotomy. During the procedure acute subdural hematoma with confluent white subdural lesion was encountered. The hematoma and subdural lesion was sent for pathological evaluation and gross total resection was performed. After the procedure patient was transferred to the Neuro-ICU for continuation of management. Histologic examination of the hematoma revealed solid sheets of small-medium sized atypical hematopoietic cells with slightly irregular nuclear membranes, relatively delicate chromatin, and scattered inconspicuous punctate nucleoli and also some medium-sized atypical cells contain scant eosinophilic cytoplasm with scattered mitoses . These cells was imbedded in an acute and chronic hematoma ( Fig. 2 A,B). To confirm the final diagnosis, flow cytometry was performed and showed two neoplastic clones, consistent with acute myeloid leukemia with monocytic differentiation and a separate mature B-cell lymphoma ( Fig. 2 C) . The immunoprofile supported the presence of two clonal populations. The first clone, composed of the medium-sized cells was positive for CD34, CD43, and variable TdT. The second clone, composed of small-medium sized cells was positive for CD20, PAX-5, BCL-2, and CD43. Ki-67 proliferation rate appears more elevated in the first clone (>20%), and less elevated in the second clone (possibly up to 10%), when factoring in background reactive lymphocytes ( Fig. 2 C). Fig. 2 Histologic analysis and flow cytometry A. Hematoxylin and Eosin staining showing small-medium sized atypical hematopoietic cells with slightly irregular nuclear membranes, relatively delicate chromatin, and scattered inconspicuous punctate nucleoli and also some medium-sized atypical cells contain scant eosinophilic cytoplasm with scattered mitoses. CD20+ positive cells, which is consistent with B-cell lymphoma B. CD 43+, CD 34+, KI-67, Tdt + staining which is consistent with AML C. Flow cytometry supported the presence of two clonal populations.The first clone, composed of the medium-sized cells was positive for CD34, CD43, and variable TdT. The second clone, composed of small-medium sized cells was positive for CD20, PAX-5, BCL-2, and CD43. Ki-67 proliferation rate appears more elevated in the first clone (>20%), and less elevated in the second clone (possibly up to 10%), when factoring in background reactive lymphocytes Fig. 2

Fig. 2 Histologic analysis and flow cytometry A. Hematoxylin and Eosin staining showing small-medium sized atypical hematopoietic cells with slightly irregular nuclear membranes, …
Fig. 2 Histologic analysis and flow cytometry A. Hematoxylin and Eosin staining showing small-medium sized atypical hematopoietic cells with slightly irregular nuclear membranes, relatively delicate chromatin, and scattered inconspicuous punctate nucleoli and also some medium-sized atypical cells contain scant eosinophilic cytoplasm with scattered mitoses. CD20+ positive cells, which is consistent with B-cell lymphoma B. CD 43+, CD 34+, KI-67, Tdt + staining which is consistent with AML C. Flow cytometry supported the presence of two clonal populations.The first clone, composed of the medium-sized cells was positive for CD34, CD43, and variable TdT. The second clone, composed of small-medium sized cells was positive for CD20, PAX-5, BCL-2, and CD43. Ki-67 proliferation rate appears more elevated in the first clone (>20%), and less elevated in the second clone (possibly up to 10%), when factoring in background reactive lymphocytes Fig. 2

After the craniotomy patient remained critically ill. Family made the decision to transfer the patient to the hospice.

Discussion and conclusion

Myeloid sarcoma, which is also known as granulocytic sarcoma or chloroma, is an uncommon malignant tumor characterized by the extramedullary blast proliferation of myeloid lineages that subsequently destroy the normal architecture of adjacent tissues [ 16 ]. Myeloid sarcoma is able to invade any anatomical site in addition, it is often found concurrently in patients with previously or recently recognized acute myeloid leukemia (AML), particularly monoblastic leukemia and AML with a t(8;21) translocation [ 17 ]. Myeloid sarcoma may develop prior to the appearance of blood or bone marrow disorders, and in such cases, should be considered alongside with AML [ 18 ]. Because the incidence is extremely low, primary central nervous system myeloid sarcoma has not been reported often. Myeloid sarcoma presents with different clinical and histological pictures depending upon the primary affected site. Once a pathological diagnosis has been established, comprehensive evaluations, including bone marrow histology, immunophenotyping, chromosomal banding and fusion gene analyses should be performed in order to determine an optimum treatment regimen [ 16 ]. One study [ 16 ] revealed that patients with AML and with a t(8;21) translocation presented with sarcomas that are more frequently affecting the central nervous system. The patient that we present was found to have in addition to intracranial myeloid sarcoma also intracranial B-cell lymphoma in the same brain lesion and flow cytometry revealed two neoplastic clones, consistent with acute myeloid leukemia with monocytic differentiation and a separate mature B-cell lymphoma. The immunoprofile supported the presence of two clonal populations.

Patients with Chronic Lymphocytic Leukemia have an increased incidence risk of second malignancy [ 19 ]. Symptomatic leukemic infiltration of the brain in CLL occurs rarely [ 20 ]. Isolated intracerebral B-cell lymphoma secondary to chronic lymphocytic leukemia is rarely reported and it is generally believed, although incorrectly, that second B-cell lymphoma represents a transformation event for a patient with CLL (Richter syndrome). We are presenting a patient who had CLL for 8 months without treatment and developed acute on chronic subdural hematoma. Pathology result of the hematoma came back positive for myeloid sarcoma and B-cell lymphoma. To our knowledge, is a first case in the literature of the combined isolated intracranial myeloid sarcoma and B-cell lymphoma. Early recognition of neurological symptoms, and a precise histological diagnosis and immunophenotyping may lead to timely CNS directed treatment and reduce mortality.

Study funding

The authors report no targeted funding.

Instruction to authors

We Confirm that the manuscript complies with all instructions to authors.

Authorship requirements

I confirm that authorship requirements have been met and the final manuscript was approved by all authors.

Previous publications

I confirm that this manuscript has not been published elsewhere and is not under consideration by another journal.

Ethical guidelines

I Confirm adherence to ethical guidelines and indicate ethical approvals (IRB) and use of informed consent.

Contributions

Denis Babici: Drafting/revision of the manuscript for content, including medical writing for content; Study concept Analysis or interpretation of data.

Pamraj Sharma : Drafting/revision of the manuscript for content, including medical writing for content.

Jason DeGregorio: Senior author, Histology analysis, Drafting/revision of the manuscript for content, including medical writing for content.

Brian Snelling: Senior author, performed surgical procedure, Drafting/revision of the manuscript for content, including medical writing for content.

Khalid Hanafy: Senior author, managed patient in the Neuro-ICU, Study design and hypothesis development, Drafting/revision of the manuscript for content, including medical writing for content.

Declaration of Competing Interest

Authors confirm no conflict of interests.

References

1 Nash I. Chronic myeloid leukemia N. Engl. J. Med. 341 10 1999 765 10.1056/NEJM199909023411016 (PubMed PMID: 10475801) 10475801

2 Kaur M. Nibhoria S. Tiwana K. Bajaj A. Chhabra S. Rapid transformation of chronic lymphocytic leukemia to acute lymphoblastic leukemia: a rare case report J. Basic Clin. Pharm. 7 2 2016 60 63 10.4103/0976-0105.177702 PubMed PMID: 27057127; PubMed Central PMCID: PMC4804406 27057127 PMC4804406

3 Zarrabi M.H. Grünwald H.W. Rosner F. Chronic lymphocytic leukemia terminating in acute leukemia Arch. Intern. Med. 137 8 1977 1059–54. (PubMed PMID: 879943) 879943

4 Catovsky D. Galton D.A. Myelomonocytic leukaemia supervening on chronic lymphocytic leukaemia Lancet. 1 7697 1971 478 479 10.1016/s0140-6736(71)91091-9 (PubMed PMID: 4100352) 4100352

5 Brouet J.C. Preud’Homme J.L. Seligmann M. Bernard J. Blast cells with monoclonal surface immunoglobulin in two cases of acute blast crisis supervening on chronic lymphocytic leukaemia Br. Med. J. 4 5883 1973 23 24 10.1136/bmj.4.5883.23 PubMed PMID: 4585418; PubMed Central PMCID: PMC1587055 4585418 PMC1587055

6 Frenkel E.P. Ligler F.S. Graham M.S. Hernandez J.A. Kettman J.R. Smith R.G. Acute lymphocytic leukemic transformation of chronic lymphocytic leukemia: substantiation by flow cytometry Am. J. Hematol. 10 4 1981 391 398 10.1002/ajh.2830100409 (PubMed PMID: 6787917) 6787917

7 Kjeldsberg C.R. Marty J. Prolymphocytic transformation of chronic lymphocytic leukemia Cancer. 48 11 1981 2447 2457 doi: 10.1002/1097-0142(19811201)48:11<2447::aid-cncr2820481118>3.0.co;2-b. PubMed PMID: 7296493 7296493 10.1002/1097-0142(19811201)48:11<2447::aid-cncr2820481118>3.0.co;2-b

8 Haq A.U. Williams D.M. Clement J.R. Bowen L.M. Rapid transformation of atypical chronic lymphocytic leukemia to acute lymphoblastic leukemia J. Pak. Med. Assoc. 37 10 1987 269 272 (PubMed PMID: 3121882) 3121882

9 Jacobs A.D. Schroff R.W. Gale R.P. Acute transformation of chronic lymphocytic leukemia Med. Pediatr. Oncol. 12 5 1984 318 321 10.1002/mpo.2950120504 (PubMed PMID: 6387420) 6387420

10 Preudhomme C. Lepelley P. Lovi V. Zandecki M. Cosson A. Fenaux P. T-cell acute lymphoblastic leukemia occurring in the course of B cell chronic lymphocytic leukemia: a case report Leuk. Lymphoma 18 3–4 1995 361 364 10.3109/10428199509059632 (PubMed PMID: 8535207) 8535207

11 Bellinzona M. Roser F. Ostertag H. Gaab R.M. Saini M. Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases Eur. J. Surg. Oncol. 31 1 2005 100 105 10.1016/j.ejso.2004.10.002 (PubMed PMID: 15642434) 15642434

12 Benouaich A. Delord J.P. Danjou M. Richaud J. Urocoste E. Soum F. Primary dural lymphoma: a report of two cases with review of the literature Rev. Neurol. (Paris) 159 6–7 Pt 1 2003 652 658 (PubMed PMID: 12910073) 12910073

13 Iwamoto F.M. DeAngelis L.M. Abrey L.E. Primary dural lymphomas: a clinicopathologic study of treatment and outcome in eight patients Neurology. 66 11 2006 1763 1765 10.1212/01.wnl.0000218284.23872.eb (PubMed PMID: 16769960) 16769960

14 Galarza M. Gazzeri R. Elfeky H.A. Johnson R.R. Primary diffuse large B-cell lymphoma of the dura mater and cranial vault. Case report and literature review Neurosurg. Focus. 21 5 2006 E10 Epub 20061115 10.3171/foc.2006.21.5.11 (PubMed PMID: 17134112) 17134112

15 Yamada S.M. Ikawa N. Toyonaga S. Nakabayashi H. Chang Park K. Shimizu K. Primary malignant B-cell-type dural lymphoma: case report Surg. Neurol. 66 5 2006 539 543 discussion 43. Epub 20060721 10.1016/j.surneu.2006.02.033 PubMed PMID: 17084207 17084207

16 Nishimura S. Kyuma Y. Kamijo A. Maruta A. Isolated recurrence of granulocytic sarcoma manifesting as extra- and intracranial masses--case report Neurol. Med. Chir. (Tokyo) 44 6 2004 311 316 10.2176/nmc.44.311 (PubMed PMID: 15253547) 15253547

17 Ishihara H. Kanamori M. Kawaguchi Y. Nakamura H. Kimura T. Adjacent segment disease after anterior cervical interbody fusion Spine J. 4 6 2004 624 628 10.1016/j.spinee.2004.04.011 (PubMed PMID: 15541693) 15541693

18 Qian J. Cui Q.U. Liu Y. Li X. Sun X. Zhu H. Isolated primary intracranial myeloid sarcoma with neuromeningeal infiltration: A case report Oncol. Lett. 9 4 2015 1647 1650 Epub 20150213 10.3892/ol.2015.2964 PubMed PMID: 25789016; PubMed Central PMCID: PMC4356429 25789016 PMC4356429

19 Kyasa M.J. Hazlett L. Parrish R.S. Schichman S.A. Zent C.S. Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death Leuk. Lymphoma 45 3 2004 507 513 10.1080/10428190310001612939 (PubMed PMID: 15160912) 15160912

20 Wanquet A. Birsen R. Bonnet C. Boubaya M. Choquet S. Dupuis J. Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients Br. J. Haematol. 176 1 2017 37 49 Epub 20161111 10.1111/bjh.14387 PubMed PMID: 27858991 27858991

Acknowledgements

The authors wish to thank the patient for agreeing with this case report.

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.